Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III…

Overview of attention for article published in Journal of Clinical Oncology, December 2018

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (95th percentile)
Good Attention Score compared to outputs of the same age and source (72nd percentile)

Mentioned by

news: 4 news outlets
policy: 2 policy sources

twitter: 15 X users
facebook: 1 Facebook page

Citations

dimensions_citation: 256 Dimensions

Readers on

mendeley: 173 Mendeley

Summary News Policy documents X Facebook Dimensions citations

So far, Altmetric has seen 16 X posts from 15 X users, with an upper bound of 64,263 followers.

RT @DrRaulCordoba: #OncoAlert #lymsm Fixed Duration of #Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia #CLL Eradi…

Reply Repost Favourite

RT @DrRaulCordoba: #OncoAlert #lymsm Fixed Duration of #Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia #CLL Eradi…

Reply Repost Favourite

RT @DrRaulCordoba: #OncoAlert #lymsm Fixed Duration of #Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia #CLL Eradi…

Reply Repost Favourite

RT @DrRaulCordoba: #OncoAlert #lymsm Fixed Duration of #Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia #CLL Eradi…

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 12 additional X posts.